NIAID conducts and supports basic and applied research to better understand, treat, and ultimately prevent infectious, immunologic, and allergic diseases. For more than 60 years, NIAID research has led to new therapies, vaccines, diagnostic tests, and other technologies that have improved the health of millions of people in the United States and around the world. NIAID is one of the 27 Institutes and Centers of the National Institutes of Health (NIH).
Areas of Study at NIAID
NIAID is working to better understand HIV and how it causes disease, find new tools to prevent HIV infection, develop new and more effective treatments for HIV-infected people, and find a cure.
NIAID conducts and supports research on nearly 300 infectious agents and investigates the biological properties of these pathogens and the immune system’s responses to them Findings from this research are vital to NIAID efforts to create vaccines, drugs, and diagnostic tools to better diagnose, prevent, and treat infectious diseases.
NIAID supports basic and clinical research to increase our understanding of the causes and mechanisms that lead to the development of allergic and immunologic diseases and to expand knowledge that can be applied to improving techniques of diagnosis, treatment, and prevention.
NIAID laboratories and NIAID-funded researchers have made many notable scientific advances, bringing us closer to much-needed vaccines and treatments, and expanding our knowledge of rare conditions and disorders. See examples of how public investment in biomedical research can advance science and benefit human health.
Advancing Worldwide Health
NIAID global research helps to protect the United States against infectious disease threats and to improve the health of millions of people around the world, promoting international economic and political stability.
NIAID supports research and early development of medical countermeasures against terrorist threats from infectious diseases, radiation exposure and chemical threats to the civilian population. NIAID’s biodefense research is integrated into its larger emerging and re‐emerging infectious diseases portfolio that uses sophisticated genomic and proteomic platforms focused on developing broad‐spectrum therapies effective against entire classes of pathogens.
NIAID has a robust program of research devoted to better understanding, preventing, and treating Neglected Tropical Diseases (NTDs). Studies conducted and supported by NIAID have led to important new discoveries about the microbes that cause NTDs, the identification of targets for potential new drugs and vaccines, and the development of strategies for controlling organisms that transmit NTD-causing agents to humans.